Skip to content

Efficacy and Safety of Catechu Decoction Irrigation for Non-Puerperal Mastitis in the Ulcerative Stage: A Single-center, Open-label Randomized Controlled Trial

Clinical Efficacy Observation of Catechu Decoction Irrigation for Sinus Tracts in Non-Puerperal Mastitis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000391
Enrollment
Unknown
Registered
2026-02-13
Start date
2026-02-21
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Puerperal Mastitis

Interventions

Treatment Group:Catechu water decoction irrigation
Control Group:normal saline flush

Sponsors

The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Female, age = 18 years; 2) Meets diagnostic criteria for non-lactational mastitis (granulomatous mastitis or plasmacytic mastitis); 3) Is in the fistula stage (defined as: after drainage of an abscess via incision, aspiration, or spontaneous rupture, the fistula persists for more than 2 weeks and is confirmed by clinical examination or breast ultrasound to be unhealed with evidence of sinus tract, pus cavity, or hypoechoic area);

Exclusion criteria

Exclusion criteria: 1) Pathological examination confirms the presence of Mycobacterium tuberculosis or malignant tumor cells in the tissue; 2) Pregnant or breastfeeding women; 3) Individuals participating in other interventional clinical trials, or those who, during the intervention period specified in this study, self-administer other local or systemic treatments for breast fistulas (e.g., systemic use of antibiotics, corticosteroids, or other traditional Chinese medicine external therapies); 4) Patients with severe abnormalities in heart, liver, or kidney function, or uncontrolled hypertension (e.g., systolic blood pressure =160 mmHg and/or diastolic blood pressure =100 mmHg after drug treatment) or diabetes (e.g., fasting blood glucose =11.1 mmol/L or glycated hemoglobin =9%); 5) Individuals with mental illness or cognitive impairments who are unable to cooperate with the intervention and assessment; 6) Known allergy to catechu or any excipients in the formulation; 7) Investigators believe there are any circumstances that may affect the implementation of the trial protocol or assessment, or consider the patient unsuitable for participation in this study for any other reason.

Design outcomes

Primary

MeasureTime frame
Complete Clinical Response (CCR) Rate;

Secondary

MeasureTime frame
Time to Sinus Tract Closure;Ultrasonographic Sinus Tract Cross-Sectional Area (cm²);Size of Inflammatory Mass Associated with Sinus Tract;Pain Score During Irrigation (assessed by Visual Analog Scale, VAS);Imaging Response Rate at 3 Months Post-Closure;Recurrence Rate;Non-Puerperal Mastitis Ulcerative Stage Score (NPM-US Score);

Countries

China

Contacts

Public ContactXiufei Gao

The First Affiliated Hospital of Zhejiang Chinese Medical University

gaoxiufei@zcmu.edu.cn13868186611

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Mar 14, 2026